undamentalytics Newsletter
Sign in

Fortress Biotech, Inc. income statement

In fiscal 2025, Fortress Biotech, Inc. reported revenue of $63.3m, up 9.7% on the year before, operating income of −$70.2m (a -111.0% margin) and net income of $6.8m, or −$0.07 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue00116188273746697685586368
Cost of revenue————461115323123212124
Gross profit————184212631374562374245
Research and development261030354887816412913510657121
Selling, general and administrative—————5356618711491889669
Selling and marketing——3610—————————
General and administrative1010192851—————————
Operating income−36−21−51−66−90−120−111−94−189−204−142−110−70−29
Interest expense21146—1215151215141010
Net interest income————000———————
Income before tax——−54−71−98−131−102−103−164−213−154−121−34146
Income tax——0020010010−15
Net income−37−20−48−55−67−84−40−47−65−87−61−467112
Diluted EPS−$1.22−$0.56−$1.24−$1.38−$1.61−$1.94−$0.73−$0.65−$0.79−$15.97−$8.47−$2.69−$0.07$3.56
Diluted shares (average)2m2m3m3m3m3m4m5m5m6m8m21m28m31m
EBITDA−36−21−51−65−89−119−109−92−186−200−140−109−70−29

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FBIO vs RXRXCYTK vs FBIOABCL vs FBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fortress Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fortress Biotech, Inc.